Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODULO: DOR/3TC vs DTG/3TC Maintenance in HIV
NCT06774872Phase 2Recruiting
- Sponsor
- Centre de Recherches et d'Études sur la Pathologie Tropicale et le Sida
- Start
- Apr 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of doravirine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Centre de Recherches et d'Études sur la Pathologie Tropicale et le Sida. Primary endpoint: Virological efficacy (maintenance of virological success) at 48 weeks. Started Apr 2025; status: recruiting.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06774872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06774872.